ADMA Biologics, Inc. (ADMA) Monday announced preliminary revenue for fiscal 2024 of between $417 million and 425 million, up from the previous guidance of $415 million.
Analysts on average expect revenue of $423.19 million for the year.
Looking ahead to 2025, the company sees revenue to exceed $485 million. Net income for the year is expected to be more than $170 million and adjusted EBITDA, or adjusted earnings before interest, taxes, depreciation, and amortization to be above $220 million.
By 20230, the company expects to generate more than $1 billion in annual revenue.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.